Afficher la notice abrégée

Optical coherence tomography angiography in diabetic macular edema treated with intravitreal aflibercept: a 48-week observational study (the DOCTA study)

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorKOROBELNIK, Jean-Francois
ORCID: 0000-0002-4438-9535
IDREF: 028739272
dc.contributor.authorGAUCHER, David
dc.contributor.authorBAILLIF, Stephanie
dc.contributor.authorCREUZOT-GARCHER, Catherine
dc.contributor.authorKODJIKIAN, Laurent
dc.contributor.authorWEBER, Michel
dc.date.accessioned2023-03-15T10:49:13Z
dc.date.available2023-03-15T10:49:13Z
dc.date.issued2023-01-16
dc.identifier.issn1423-0267 (Electronic) 0030-3755 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/172319
dc.description.abstractEnINTRODUCTION: Central vision loss due to diabetic macular edema (DME) is related to the macular edema itself, but also in some cases to alterations of the foveal avascular zone (FAZ). The aim of this trial was to study changes in macular vessels in eyes with DME treated with aflibercept using optical coherence tomography angiography (OCTA). METHODS: This was a longitudinal, prospective, non-controlled, single arm study. The primary objective was the quantitative assessment of macular vessels over time in patients with DME treated with intravitreal aflibercept during a 48-week follow-up using OCTA. RESULTS: Twenty-six DME eyes from 26 patients were included (mean age, 64.6 years; women, 53.8%; prior anti-VEGF treatment, 46.1%). Each eye received a mean (SD) of 7.2 (2.2) injections. The parameters of the FAZ did not change during the 48-week follow-up: the mean (SD) FAZ area varied from 0.19 (0.19) mm2 at baseline (n=22) to 0.23 (0.20) mm2 at week 48 (n=15), boundary from 1.54 (1.21) to 2.04 (1.20) mm and circularity from 0.45 (0.33) % to 0.57 (0.20) %. There was no change in perfusion density and vessel density of the macula in the 3-mm circle. As expected, mean central retinal thickness, macular volume and visual acuity improved during follow-up. DISCUSSION/CONCLUSION: No change in macular perfusion was observed in eyes with DME during a 48-week follow-up after intravitreal injections of aflibercept. Randomized controlled trials using OCT-angiography in large populations with extended observation periods are needed to assess changes in macular vessels after intravitreal anti-VEGF treatment.
dc.language.isoENen_US
dc.subject.enDiabetic macular edema
dc.subject.enAflibercept
dc.subject.enIntravitreal anti-vascular endothelial growth factor
dc.subject.enOptical coherence tomography angiography
dc.subject.enMacular vessels
dc.subject.enFoveal avascular zone
dc.title.enOptical coherence tomography angiography in diabetic macular edema treated with intravitreal aflibercept: a 48-week observational study (the DOCTA study)
dc.title.alternativeOphthalmologicaen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1159/000528426en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed36646050en_US
bordeaux.journalOphthalmologicaen_US
bordeaux.page1-10
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamLEHA_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Ophthalmologica&rft.date=2023-01-16&rft.spage=1-10&rft.epage=1-10&rft.eissn=1423-0267%20(Electronic)%200030-3755%20(Linking)&rft.issn=1423-0267%20(Electronic)%200030-3755%20(Linking)&rft.au=KOROBELNIK,%20Jean-Francois&GAUCHER,%20David&BAILLIF,%20Stephanie&CREUZOT-GARCHER,%20Catherine&KODJIKIAN,%20Laurent&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée